NEW YORK, June 22, 2026 (GLOBE NEWSWIRE) -- Prolium Bioscience, Inc. (Prolium), a clinical stage biotechnology company, today announced that the first patient has been dosed in a multinational, ...
Phase 1/2 SSc study is expected to enroll patients at over 20 participating clinical sites in at least five countries Recently completed Phase 1 Single Ascending Dose study of PRO-203 in healthy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results